MX1
0.045
80%
BUY
0.012
-36.8%
M24
0.038
58.3%
3DA
0.175
-36.4%
RWL
0.305
56.4%
ATT
0.004
-33.3%
VTA
0.029
52.6%
CHM
0.005
-28.6%
GL1
1.005
51.1%
MEK
0.1
-28.6%
AMD
0.034
47.8%
TGN
0.285
-26%
VR8
0.076
43.4%
BNL
0.003
-25%
A8G
0.28
33.3%
IMA
0.012
-25%
CTN
0.06
33.3%
TMX
0.003
-25%
SPQ
0.004
33.3%
WHK
0.003
-25%
RCT
4.64
33%
MXI
1.8
-23.1%
MHK
0.145
31.8%
TUA
1.78
-22.9%
WTM
0.795
31.4%
KYN
0.03
-21.1%
MBG
0.21
27.3%
LMG
0.015
-21.1%
TRJ
0.26
26.8%
AM5
0.004
-20%
CMO
0.005
25%
FIN
0.004
-20%
ELT
0.45
25%
GLL
0.004
-20%
IPD
0.005
25%
CC9
0.045
-19.6%
LRM
0.02
25%
OFX
0.6
-19.5%
CLV
1.08
24.9%
GLN
0.315
-19.2%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Transcription of The Stock Network Interview with HeraMED (ASX:HMD), CEO & MD Anoushka Gungadin Anoushka Gungadin:...

Transcription of The Stock Network Interview with Kalina Power (ASX:KPO), Executive Director Tim Horgan Tim Horgan:...

Transcription of The Stock Network Interview with Weebit Nano (ASX:WBT), CEO Coby Hanoch Coby Hanoch: I'm...

The first-in-human trial returned a favourable safety profile, with the cream staying local and no...

Transcription of The Stock Network Interview with Overwatch Technologies (ASX:OWL), Co-Founder and Managing Director Oscar...

Transcription of The Stock Network Interview with Chariot Resources (ASX:CC9), Executive Chair and Managing Director...

Transcription of The Stock Network Interview with Impact Minerals (ASX:IPT), Managing Director Dr Mike Jones Lel...

Transcription of The Stock Network Interview with EBR Systems (ASX:EBR), Senior Director of Research &...

Transcription of The Stock Network Interview with Metals Australia (ASX:MLS), CEO Paul Ferguson Lel Smits: A...

Transcription of The Stock Network Interview with GoldArc Resources (ASX:GA8), Managing Director Paul Stephen Lel Smits:...

WiSE CRT is the first leadless CRT system to win FDA pre-market approval. 117 US...

Acrux says FDA feedback confirms its Phase I and II data give it a clear...

Get the latest ASX stock market news delivered to your inbox

By proceeding, you can confirm you understand that we handle personal informational in accordance with our Privacy Policy